References
- Vallat VP, Gilleaudeau P, Battat L, et al. PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy. J Exp Med 1994;180:283–296
- Fotiadou C, Lazaridou E, Ioannides D. Management of psoriasis in adolescence. Adolesc Health Med Ther 2014;5:25–34
- Kutlubay Z, Karakuş Ö, Engin B, Serdaroğlu S. Psoriasis: klinik tiplere göre tedavi yaklaşımı. Dermatoz 2012;3:33–38
- Piaserico S1, Conti A, Lo Console F, et al. Efficacy and safety of systemic treatments for psoriasis in elderly patients. Acta Derm Venereol 2014;94:293–297
- Mease P. Methotrexate in psoriatic arthritis. Bull Hosp Jt Dis 2013;71:41–45
- Barbagallo J, Spann CT, Tutrone WD, Weinberg JM. UVB phototherapy for the treatment of psoriasis: a review and update. Cutis 2001;68:345–347
- Krueger JG, Wolfe JT, Tsukifuji R, et al. Successful ultraviolet B treatment of psoriasis is accompanied by a reversal keratinocyte pathology and by selective depletion of intraepidermal T cells. J Exp Med 1995;182:2057–2068
- Rácz E, Prens EP, Kurek D, et al. Effective treatment of psoriasis with narrow-band UVB phototherapy is linked to suppression of the IFN and Th17 pathways. J Invest Dermatol 2011;131:1547–1558
- Ozawa M, Ferenczi K, Kikuchi T, et al. 312-nanometer ultraviolet B light (narrow-band UVB) induces apoptosis of T cells within psoriatic lesions. J Exp Med 1999;189:711–718
- Duthie MS, Kimber I, Norval M. The effects of ultraviolet radiation on the human immune system. Br J Dermatol 1999;140:995–1009
- Coven TR, Burack LH, Gilleaudeau R, et al. Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B. Arch Dermatol 1997;133:1514–1522
- Ranganathan P, Mcleod HL. Methotrexate pharmacogenetics: the first step towards individualized therapy in rheumatoid arthritis. Arthritis Rheum 2006;54:1366–1377
- Saporito FC, Menter MA. Methotrexate and psoriasis in the era of new biologic agents. J Am Acad Dermatol 2004;50:301–309
- Jeffes EW 3rd, McCullough JL, Pittelkow MR, et al. Methotrexate therapy of psoriasis: differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate. J Invest Dermatol 1995;104:183–188
- Dogra S, Mahajan R. Systemic methotrexate therapy for psoriasis: past, present and future. Clin Exp Dermatol 2013;38:573–588
- Eskicirak B, Zemheri E, Cerkezoglu A. The treatment of psoriasis vulgaris: 1% topical methotrexate gel. Int J Dermatol 2006;45:965–969
- Gottlieb SL, Hayes E, Gilleaudeau P, et al. Cellular actions of etretinate in psoriasis enhanced epidermal differentiation and reduced cell-mediated inflammation are unexpected outcomes. J Cutan Pathol 1996;23:404–418